Business Context and Reporting Period
Company: Tivic Health Systems, Inc. (Note: Input metadata referenced "Valion Bio," but the filing text identifies the registrant as Tivic Health Systems, Inc., trading as TIVC).
Reporting Period: Quarterly Report on Form 10-Q for the period ended September 30, 2024.
Business Overview: Tivic Health is a health tech company focused on non-invasive bioelectronic medicine. Its primary commercial product is ClearUP Sinus Pain Relief, an FDA-approved handheld device for sinus pain and congestion. The company is also developing a clinical-stage platform for non-invasive vagus nerve stimulation (ncVNS).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $126 | $282 | $600 | $819 |
| Gross Profit | $44 | $108 | $241 | $282 |
| Gross Margin | 35% | 38% | 40% | 34% |
| Net Loss | $(1,431) | $(1,760) | $(4,178) | $(6,001) |
| Operating Cash Flow | N/A | N/A | $(4,360) | $(6,737) |
| Cash and Equivalents (End of Period) | $2,189 | N/A | $2,189 | N/A |
| Working Capital | $2,603 | N/A | $2,603 | N/A |
| Accumulated Deficit | $(42,064) | N/A | $(42,064) | N/A |
Note: Q3 Operating Cash Flow is not explicitly broken out in the provided text; only the nine-month figure is available.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 56% in Q3 2024 compared to Q3 2023, driven by a 55% drop in unit sales. For the nine months ended September 30, revenue declined 27% due to a 36% decrease in unit sales, partially offset by a 13% increase in average sales price.
- Expense Reduction: Total operating expenses decreased by 21% in Q3 and 31% for the nine-month period compared to the prior year. This was achieved through reduced headcount, lower consulting fees, and the elimination of significant lease expenses following the termination of the Hayward headquarters lease in May 2024.
- Cost of Sales: Cost of sales decreased 53% in Q3 and 34% for the nine months, primarily due to lower sales volume. However, the company incurred $21,000 in disposal costs related to transitioning logistics providers in August 2024.
- Capital Structure: In May 2024, the company raised approximately $3.3 million in net proceeds from a registered public offering of 4.71 million shares and warrants. In September 2024, an Equity Distribution Agreement (ATM) was established with Maxim Group LLC.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With cash of $2.2 million and a burn rate resulting in negative operating cash flows of $4.4 million for the nine months ended September 30, 2024, the company expects to require additional capital to fund operations and R&D.
- Nasdaq Compliance: The company received a notification from Nasdaq on June 28, 2024, regarding non-compliance with the minimum bid price requirement (stock price below $1.00 for 33 consecutive days). The company has until December 26, 2024, to regain compliance or risk delisting.
- Operational Updates:
- Completed a pilot study with The Feinstein Institutes confirming the effectiveness of the ncVNS approach.
- Terminated the ALOM fulfillment agreement in August 2024 to reduce costs, transitioning to in-house assembly and alternate third-party logistics.
- Launched ClearUP 2.0 with improved power management.
- Risks: Key risks include the inability to secure additional financing, potential delisting from Nasdaq, supply chain constraints, and the failure of clinical trials for the ncVNS platform.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.2 million cash balance against the current burn rate and the timeline for securing additional equity or debt financing.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the December 26, 2024 deadline to avoid delisting.
- Revenue Trends: Assess whether the decline in unit sales for ClearUP is a temporary fluctuation or a structural shift in demand, given the 56% Q3 drop.
- ncVNS Progress: Track the enrollment and results of the ongoing Phase 1a optimization study with The Feinstein Institutes, as this is critical for future valuation.
- ATM Utilization: Monitor the utilization of the new Equity Distribution Agreement with Maxim Group to gauge the company's ability to raise capital on a continuous basis.